- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04870476
Feasibility and Acceptability of the Internet-delivered Treatment "One Step at the Time" for Bodily Distress Syndrome
"One Step at a Time" - an Internet-delivered Treatment for Patients Moderately Impaired by Bodily Distress Syndrome. A Feasibility Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
"One Step at the Time" - Internet-delivered Treatment for Patients Moderately Impaired by Bodily Distress Syndrome. A Feasibility Pilot Study.
Lisbeth Frostholm, Andreas Schröder, Johanne Liv Agger, Heidi Frølund Pedersen
Objective The objective of this uncontrolled pilot study is to test the feasibility of a future RCT by exploring the acceptability and effect of an internet-delivered treatment program, "One step at the time", for patients moderately affected by Bodily Distress Syndrome (BDS). The focus of the feasibility trial is evaluation of treatment response, treatment satisfaction, program utility, recruitment and retention rates, data completion rates, and time requirement. The primary feasibility criterion is an a priori defined change in patient-rated physical health from before to after treatment.
Design This study is designed as an uncontrolled, single-arm, single-center feasibility pilot study.
Participants The study includes 25 participants included from February to July 2020. The participants are recruited from The Research Clinic for Functional Disorders and Psychosomatics and The Pain and Headache Clinic, Aarhus University Hospital, Denmark, to which patients with multiple functional somatic symptoms are consecutively referred from GPs, medical specialists and hospital departments. Patients moderately affected by multiple symptoms are screened for eligibility by the eligibility criteria below. They undergo thorough diagnostic assessment by a medical doctor specialized in functional disorders after a thorough physical and psychological assessment including diagnostic interview (Schedules for Clinical Assessment in Neuropsychiatry), physical examination including blood pressure, blood test and a review of all medical records.
Eligibility criteria
Inclusion criteria:
- Meet the diagnostic criteria for Bodily distress syndrome (BDS) with 2-3 of 4 symptom clusters
- Moderate impact on daily life (self-reliant at home, can participate in activities outside the home)
- Symptoms lasting for at least 6 months
- 18-60 years at the time of inclusion
8. Previous stable educational or occupational attachment until at least 2 years prior to enrollment and expecting to return to occupational or educational activity 10. Motivation and time to participate in a psychological treatment program for treatment of BDS 11. IT skills and access to internet and computer/tablet 12. Willingness to engage in working with illness perception and behavioral change
Exclusion criteria:
5. Presence of other physical condition if the symptoms of this condition can not clearly be separated from symptoms of BDS or the condition is unstable/untreated 6. Current moderate or severe psychiatric disorder that substantially impacts daily life or demands special, individualized treatment, or clinical suspicion hereof, e.g. treatment-demanding depression or personality disorder 7. Current continuous treatment with opioids and drugs with opioid-like properties 9. Previous psychological treatment targeting BDS
Intervention "One step at the time" is a newly developed internet-delivered therapist-assisted treatment program for patients with BDS. The 11 modules + 1 module for relatives are primarily text-based but also contain audio files with guided exercises and videos with former patients. During a period of 14 weeks, patients are guided through the program modules assisted by a trained psychologist or psychiatrist.
Course If eligible and willing to participate, patients are included in the pilot study and assigned to a therapist (a trained psychologist or psychiatrist from The Research Clinic for Functional Disorders). Patients are contacted by telephone by the therapist and guided to login to the program platform and initiate treatment. The therapist follows the patient through the 11 treatment modules and provides guidance when needed. Patients and therapists primarily communicate through asynchronously written messages, and occasionally by telephone. Treatment duration is 14 weeks.
Measurements Patient-rated outcome measures are collected through a web-based program at the time of screening (before inclusion) (T0, baseline), before treatment (T1, 2 weeks), at end of treatment (T3, 16 weeks) and at 3 months after treatment (follow-up, 28 months) (T4). Clinician-rated outcome measures are collected at the time of diagnostic assessment and at end of treatment.
Patient-rated measures include:
- physical, mental, and social health measured by SF-36 with emphasis on the aggregate score physical health
- overall health improvement measured by the 5-point clinical global improvement scale (CGI)
- symptom intensity and symptom interference measured by The Numeric Rating Scale
- symptoms of anxiety, depression, and somatization measured by relevant subscores of the 92-item Danish version of the Symptom Checklist (SCL-92)
- bodily symptoms measured by The BDS Checklist
- illness worry measured by Whiteley-7
- illness perception measured by Brief-IPQ
- illness behaviour measured by BRIQ
- sense of meaningfulness measured by The Sources of Meaning and Meaning in Life Questionnaire (SoMe short version)
- treatment expectancy, rationale credibility, and treatment satisfaction measured by the credibility/expectancy questionnaire
- work performance and work absence measured questionnaire for Costs associated with Psychiatric Illness (TiC-P)
- demographic variables
- negative effects of psychotherapy measured by the inventory for the assessment of negative effects of psychotherapy (INEP)
- program utility measured by the Internet Evaluation and Utility Questionnaire
- patients' experience and satisfaction with assessment and treatment measured by questionnaires and qualitative semi-structured interviews
Other measures include:
- clinician-rated improvement measured by the 5-point clinical global improvement scale (CGI),
- therapist time spent per patient
- clinician-rated program utility measured by the Internet Evaluation and Utility Questionnaire
- recruitment and retention rates and data completeness.
Feasibility outcomes
1) Changes in patient-rated physical health from before to after the treatment measured by the SF-36 aggregate score Physical Health.
- Recruitment and retention rates, time requirements and data completeness as measured by the rate of eligible patients willing to participate, the rate of included patients completing the treatment program (defined as completion of at least 5 modules), therapists' time spent per patient, and the rate of treatment completers providing full data.
- Patients' treatment satisfaction and assessment of program utility as measured by the credibility/expectancy questionnaire, a patient satisfaction questionnaire and the internet evaluation and utility questionnaire.
- Patients' and therapists' impression of treatment effect as measured by the clinical global improvement 5-point Likert scale).
Feasibility criteria
We regard a future study testing the treatment program "One step at the time" in an RCT as feasible if:
- A mean change in the SF-36 aggregate score Physical Health is at least +2.0 points from baseline (T0, baseline) or inclusion (T1, 2 weeks) to end of treatment (T2, 16 weeks) for treatment completers.
- 75% of the patients included in the study complete the treatment program (defined as completion of at least 5 of 11 modules) and 90% of treatment completers provide full data
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Meet the diagnostic criteria for Bodily distress syndrome (BDS) with 2-3 of 4 symptom clusters
- Moderate impact on daily life (self-reliant at home, can participate in activities outside the home)
- Symptoms lasting for at least 6 months
- 18-60 years at the time of inclusion
- Previous stable educational or occupational attachment until at least 2 years prior to enrollment and expecting to return to occupational or educational activity
- Motivation and time to participate in a psychological treatment program for treatment of BDS
- IT skills and access to internet and computer/tablet
- Willingness to engage in working with illness perception and behavioral change
Exclusion Criteria:
- Presence of other physical condition if the symptoms of this condition can not clearly be separated from symptoms of BDS or the condition is unstable/untreated
- Current moderate or severe psychiatric disorder that substantially impacts daily life or demands special, individualized treatment, or clinical suspicion hereof, e.g. treatment-demanding depression or personality disorder
- Current continuous treatment with opioids and drugs with opioid-like properties
- Previous psychological treatment targeting BDS
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Internet-delivered treatment: "One step at the time"
Internet-delivered treatment: "One step at the time".
All participants receive the internet-delivered therapist-assisted 11-modules treatment program "One step at the time".
|
The guided internet treatment program consists of 11 modules (+ 1 module for relatives) activated consecutively over a period of 14 weeks.
The content is written psychoeducation, patient videos, audio exercises and exposure exercises.
The program is therapist-guided; hence all patients will receive support primarily from a specific therapist during the 14 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in physical Health
Time Frame: Baseline, before treatment (2 weeks), after treatment (16 weeks) and at 3 month follow up (28 months)
|
Patient-rated physical health measured by the SF-36 aggregate score Physical Health
|
Baseline, before treatment (2 weeks), after treatment (16 weeks) and at 3 month follow up (28 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SF-36 physical health
Time Frame: Baseline, before treatment (2 weeks), after treatment (16 weeks) and at 3 month follow up (28 weeks)
|
Changes in physical, mental, and social health
|
Baseline, before treatment (2 weeks), after treatment (16 weeks) and at 3 month follow up (28 weeks)
|
5-point clinical global improvement scale (CGI)
Time Frame: after treatment (14 weeks)
|
Overall health improvement
|
after treatment (14 weeks)
|
The Numeric Rating Scale
Time Frame: every 2 weeks during treatment
|
Changes in symptom intensity and symptom interference
|
every 2 weeks during treatment
|
Relevant subscores of the 92-item Danish version of the Symptom Checklist (SCL-92)
Time Frame: Baseline, before treatment (2 weeks), after treatment (16 weeks) and at 3 month follow up (28 weeks)
|
Changes in symptoms of anxiety, depression, and somatization
|
Baseline, before treatment (2 weeks), after treatment (16 weeks) and at 3 month follow up (28 weeks)
|
The BDS Checklist
Time Frame: Baseline, before treatment (2 weeks), after treatment (16 weeks) and at 3 month follow up (28 weeks)
|
Symptom checklist
|
Baseline, before treatment (2 weeks), after treatment (16 weeks) and at 3 month follow up (28 weeks)
|
Whiteley-7
Time Frame: Baseline, before treatment, after treatment and at 3 month follow up
|
Changes in illness worry
|
Baseline, before treatment, after treatment and at 3 month follow up
|
Brief-Illness perception questionnaire
Time Frame: Baseline, before treatment (2 weeks), after treatment (16 weeks) and at 3 month follow up (28 weeks)
|
Changes in illness perception
|
Baseline, before treatment (2 weeks), after treatment (16 weeks) and at 3 month follow up (28 weeks)
|
The Behavioural Responses to Illness Questionnaire (BRIQ) Changes in illness behaviour
Time Frame: Baseline, before treatment (2 weeks), after treatment (16 weeks) and at 3 month follow up (28 weeks)
|
Changes in illness behaviour
|
Baseline, before treatment (2 weeks), after treatment (16 weeks) and at 3 month follow up (28 weeks)
|
The credibility/expectancy questionnaire
Time Frame: Before treatment (2 weeks) and after treatment (16 weeks)
|
Treatment expectancy, rationale credibility, and treatment satisfaction
|
Before treatment (2 weeks) and after treatment (16 weeks)
|
Costs associated with Psychiatric Illness (TiC-P)
Time Frame: Before treatment (2 weeks) and at 3 month follow up (16 weeks)
|
Changes in work performance and work absence
|
Before treatment (2 weeks) and at 3 month follow up (16 weeks)
|
The inventory for the assessment of negative effects of psychotherapy (INEP)
Time Frame: After treatment (16 weeks)
|
Negative effects of psychotherapy
|
After treatment (16 weeks)
|
The Internet Evaluation and Utility Questionnaire
Time Frame: after treatment (16 weeks)
|
Program utility
|
after treatment (16 weeks)
|
The Sources of Meaning and Meaning in Life Questionnaire (SoMe short version)
Time Frame: Baseline, before treatment (2 weeks), after treatment (16 weeks) and at 3 month follow up (28 weeks)
|
Chnages in sense of meaningfulness and crisis of meaning
|
Baseline, before treatment (2 weeks), after treatment (16 weeks) and at 3 month follow up (28 weeks)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patients' experience and satisfaction with assessment and treatment
Time Frame: During treatment
|
Qualitative semi-structured interviews
|
During treatment
|
5-point clinical global improvement scale (CGI)
Time Frame: After treatment (16 weeks)
|
Clinician-rated improvement
|
After treatment (16 weeks)
|
Therapist time spent per patient
Time Frame: During treatment
|
Time spent per patient
|
During treatment
|
The Internet Evaluation and Utility Questionnaire
Time Frame: After treatment (16 weeks)
|
Clinician-rated program utility
|
After treatment (16 weeks)
|
Recruitment and retention rates and data completeness.
Time Frame: Baseline, before treatment (2 weeks), after treatment (16 weeks) and at 3 month follow up (28 weeks)
|
Rates of eligible patients willing to participate, completion rate (at least 5 modules) and data completeness.
|
Baseline, before treatment (2 weeks), after treatment (16 weeks) and at 3 month follow up (28 weeks)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Digestive System Diseases
- Pathologic Processes
- Central Nervous System Diseases
- Nervous System Diseases
- Virus Diseases
- Infections
- Gastrointestinal Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Colonic Diseases, Functional
- Colonic Diseases
- Intestinal Diseases
- Encephalomyelitis
- Syndrome
- Disease
- Irritable Bowel Syndrome
- Fibromyalgia
- Somatoform Disorders
- Fatigue Syndrome, Chronic
- Neurasthenia
Other Study ID Numbers
- OneStep 1.0
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Irritable Bowel Syndrome
-
ProgenaBiomeRecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome Characterized by Constipation | Irritable Bowel Syndrome Mixed | Irritable Bowel Syndrome Without Diarrhea | Irritable Bowel | Irritable Bowel Syndrome Aggravated and other conditionsUnited States
-
ClasadoCR2O B.V.RecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome - Constipation | Irritable Bowel Syndrome - Diarrhoea | Irritable Bowel Syndrome - MixedBelgium, Netherlands, United Kingdom
-
Istanbul Medipol University HospitalTepecik Training and Research Hospital; Bozyaka Training and Research Hospital and other collaboratorsRecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome MixedTurkey
-
Federal Stare Budgetary Scientific Institution,...I.M. Sechenov First Moscow State Medical University; RML INVEST, Torkhovsky...CompletedIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome MixedRussian Federation
-
University of California, Los AngelesCompletedIrritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Mixed Bowel HabitsUnited States
-
University of ViennaCompleted
-
Thomayer University HospitalCharles University, Czech RepublicActive, not recruitingIrritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome MixedCzechia
-
Shahid Beheshti University of Medical SciencesCompletedIrritable Bowel DiseaseIran, Islamic Republic of
-
Universidad Autonoma de ChihuahuaNot yet recruitingIrritable Bowel Syndrome | Constipation-predominant Irritable Bowel Syndrome | Diarrhea- Irritable Bowel Syndrome
-
Vasily IsakovRussian Science Foundation; Azbuka vkusa; Federal Research Centre of Nutrition...CompletedIrritable Bowel Syndrome With Constipation | Constipation-predominant Irritable Bowel SyndromeRussian Federation
Clinical Trials on Internet-delivered treatment: "One step at the time"
-
University of AarhusAarhus University Hospital; Sygehus LillebaeltRecruitingIrritable Bowel Syndrome | Fibromyalgia | Chronic Fatigue Syndrome | Bodily Distress Disorder Moderate | Bodily Distress Disorder Severe | SomatizationDenmark
-
University of VirginiaNational Institute of Mental Health (NIMH)CompletedSleep Initiation and Maintenance DisordersUnited States
-
The University of Texas Health Science Center,...WithdrawnDeep Neck Space InfectionsUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Memorial Sloan Kettering Cancer CenterWeill Medical College of Cornell University; McMaster UniversityCompleted
-
Luxembourg Institute of HealthLuxembourg Centre for Systems Biomedicine; FNR (Luxembourg National Research... and other collaboratorsNot yet recruiting
-
Mansoura UniversityCompletedUrinary Incontinence | Urinary Bladder Cancer | IncontinenceEgypt
-
Hospices Civils de LyonUnknown
-
Memorial Sloan Kettering Cancer CenterCelgene CorporationCompletedLeukemia | Chronic Lymphocytic LeukemiaUnited States
-
Memorial Sloan Kettering Cancer CenterPfizer; Dana-Farber Cancer Institute; University of Pittsburgh; University of VirginiaCompletedNeurofibromatosis | Meningioma | CNS Cancer | Hemangioblastoma | Intracranial HemangiopericytomaUnited States